基石药业-B（2616.HK）于6月3日宣布，其首席执行官、董事会成员及高级管理层已共同启动一项股份购买计划。根据该计划，相关人士拟自2026年6月起，在公开市场联合购入总计200万至500万股公司股份。
此项联合购股行动彰显了公司核心管理层对基石药业-B未来长期发展前景的坚定信心，并体现了其与股东利益深度绑定的决心。管理层通过真金白银投入市场，直接参与股份增持，旨在向投资者传递积极的信号。
计划的具体实施细节将遵循相关市场规则与披露要求。市场分析人士认为，此类内部人士的集体购股行为，通常被视作对公司内在价值和增长潜力的认可，可能对市场情绪产生正面影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.